Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia
Academic Article
Overview
MeSH Major
Antineoplastic Agents
Benzamides
Leukemia, Lymphocytic, Chronic, B-Cell
Protein-Tyrosine Kinases
Pyrazines
abstract
In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).
